Patents by Inventor Henning Steinhagen

Henning Steinhagen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS
    Publication number: 20120208805
    Abstract: The invention relates to novel compounds of formula I where X, A?, Q1, Q2, Q3, R2, R3, R4, R5, R6, R7, R8 and R9 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.
    Type: Application
    Filed: April 20, 2012
    Publication date: August 16, 2012
    Applicant: SANOFI
    Inventors: Uwe HEINELT, Volkmar WEHNER, Matthias HERRMANN, Karl SCHOENAFINGER, Henning STEINHAGEN
  • Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals
    Patent number: 8211885
    Abstract: The present invention relates to cyclic indole-3-carboxamides of the formula I, wherein A, R, R10, R20, R30, R40, n, p and q have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they inhibit the enzyme renin and modulate the activity of the renin-angiotensin system, and are useful for the treatment of diseases such as hypertension, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: July 28, 2010
    Date of Patent: July 3, 2012
    Assignee: Sanofi-Aventis
    Inventors: Henning Steinhagen, Bodo Scheiper, Hans Matter, Hans Ulrich Stilz, Gary McCort
  • Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments
    Patent number: 8198272
    Abstract: The invention relates to novel compounds of formula I where X, A?, Q1, Q2, Q3, R2, R3, R4, R5, R6, R7, R8 and R9 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: June 12, 2012
    Assignee: Sanofi-Aventis
    Inventors: Uwe Heinelt, Volkmar Wehner, Matthias Herrmann, Karl Schoenafinger, Henning Steinhagen
  • Aryl- and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their application in therapeutics
    Patent number: 8153647
    Abstract: Disclosed are compounds according to formula (I): wherein A, Q, X, Y, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein. The disclosure also relates to pharmaceutical compositions containing a compound of formula (I), to processes for preparing the compounds of formula (I), and to methods of using the compounds of formula (I).
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: April 10, 2012
    Assignee: Sanofi-Aventis
    Inventors: Jozsef Zsolt Bocskei, Gary McCort, Hans Matter, Henning Steinhagen, Bérangère Thiers
  • Malonamide derivatives with antithrombotic activity
    Patent number: 8143242
    Abstract: The present invention relates to compounds of formula I, The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are inhibitors of the blood clotting enzymes, especially factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: January 7, 2010
    Date of Patent: March 27, 2012
    Assignee: Sanofi-Aventis
    Inventors: Henning Steinhagen, Hauke Szillat, Markus Follmann, Reinhard Kirsch, Volkmar Wehner, Hans Matter, Martin Lorenz, Kent W. Neuenschwander, Anthony C. Scotese
  • Isoserine derivatives for use as coagulation factor IXa inhibitors
    Patent number: 8097758
    Abstract: The invention relates to the compounds of formula (I) having antithrombotic activity which especially inhibit blood clotting factor IXa, to methods for producing the same and to the use thereof as drugs.
    Type: Grant
    Filed: March 9, 2009
    Date of Patent: January 17, 2012
    Assignee: Sanofi-Aventis
    Inventors: Henning Steinhagen, Markus Follmann, Jochen Goerlitzer, Herman Schreuder
  • TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS
    Publication number: 20120010203
    Abstract: The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.
    Type: Application
    Filed: September 23, 2011
    Publication date: January 12, 2012
    Applicant: SANOFI-AVENTIS
    Inventors: Uwe HEINELT, Volkmar WEHNER, Matthias HERRMANN, Karl SCHOENAFINGER, Henning STEINHAGEN, Bodo SCHEIPER
  • Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments
    Patent number: 8076336
    Abstract: The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: December 13, 2011
    Assignee: Sanofi-Aventis
    Inventors: Uwe Heinelt, Volkmar Wehner, Matthias Herrmann, Karl Schoenafinger, Henning Steinhagen, Bodo Scheiper
  • Pyrazolopyridine derivatives as inhibitors of ?-Adrenergic receptor kinase 1
    Patent number: 7910602
    Abstract: The invention relates to 6-amido substituted pyrazolopyridine derivatives of the formula (I) useful as inhibitors of beta-adrenergic receptor kinase 1 (?ARK-1), compositions containing such compounds and their use for the treatment and prevention of chronic heart failure, hypertension, myocardial ischemia and hepatitis C virus (HCV) infections, and for the prevention of opiate addiction.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: March 22, 2011
    Assignee: Sanofi-Aventis
    Inventors: Henning Steinhagen, Jochen Huber, Kurt Ritter, Bernard Pirard, Kirsten Bjergarde, Marcel Patek, Martin Smrcina, Linli Wei
  • CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20110039830
    Abstract: The present invention relates to cyclic indole-3-carboxamides of the formula I, wherein A, R, R10, R20, R30, R40, n, p and q have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they inhibit the enzyme renin and modulate the activity of the renin-angiotensin system, and are useful for the treatment of diseases such as hypertension, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: July 28, 2010
    Publication date: February 17, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Henning STEINHAGEN, Bodo SCHEIPER, Hans MATTER, Hans Ulrich STILZ, Gary MCCORT
  • CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20110039861
    Abstract: The present invention relates to cyclic azaindole-3-carboxamides of the formula I, wherein A, R, R10, R20, R30, R40, Y1, Y2, Y3, Y4, n, p and q have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they inhibit the enzyme renin and modulate the activity of the renin-angiotensin system, and are useful for the treatment of diseases such as hypertension, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: July 28, 2010
    Publication date: February 17, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Henning STEINHAGEN, Bodo SCHEIPER, Hans MATTER, Gary MCCORT
  • IMIDAZOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS
    Publication number: 20110034456
    Abstract: The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, R9, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.
    Type: Application
    Filed: August 5, 2010
    Publication date: February 10, 2011
    Applicant: sanofi-aventis
    Inventors: Uwe HEINELT, Volkmar WEHNER, Matthias HERRMANN, Karl SCHOENAFINGER, Henning STEINHAGEN
  • TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS
    Publication number: 20110034452
    Abstract: The invention relates to novel compounds of formula I where X, A?, Q1, Q2 Q3, R2, R3, R4, R5, R6, R7, R8 and R9 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.
    Type: Application
    Filed: August 5, 2010
    Publication date: February 10, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Uwe HEINELT, Volkmar WEHNER, Matthias HERRMANN, Karl SCHOENAFINGER, Henning STEINHAGEN
  • TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS
    Publication number: 20110034451
    Abstract: The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.
    Type: Application
    Filed: August 5, 2010
    Publication date: February 10, 2011
    Applicant: sanofi-aventis
    Inventors: Uwe HEINELT, Volkmar WEHNER, Matthias HERRMANN, Karl SCHOENAFINGER, Henning STEINHAGEN, Bodo SCHEIPER
  • SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS
    Publication number: 20110034461
    Abstract: The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R9, Ar, Q1, Q2 and Q3 are each as defined below. The compounds of the formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of the formula I and to the use thereof as a medicament.
    Type: Application
    Filed: August 5, 2010
    Publication date: February 10, 2011
    Applicant: sanofi-aventis
    Inventors: Uwe HEINELT, Volkmar WEHNER, Matthias HERRMANN, Karl SCHOENAFINGER, Henning STEINHAGEN
  • MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY
    Publication number: 20100249101
    Abstract: The present invention relates to compounds of formula I, The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are inhibitors of the blood clotting enzymes, especially factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Application
    Filed: January 7, 2010
    Publication date: September 30, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Henning STEINHAGEN, Hauke SZILLAT, Markus FOLLMANN, Reinhard KIRSCH, Volkmar WEHNER, Hans MATTER, Martin LORENZ, Kent W. Neuenschwander, Anthony C. SCOTESE
  • ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS
    Publication number: 20090233949
    Abstract: The invention relates to the compounds of formula (I) having antithrombotic activity which especially inhibit blood clotting factor IXa, to methods for producing the same and to the use thereof as drugs.
    Type: Application
    Filed: March 9, 2009
    Publication date: September 17, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Henning STEINHAGEN, Markus FOLLMANN, Jochen GOERLITZER, Herman SCHREUDER
  • TARTRATE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS
    Publication number: 20090233961
    Abstract: The invention relates to the compounds of formula I having antithrombotic activity which especially inhibits blood clotting factor IXa, to methods for producing the same and to the use thereof as drugs.
    Type: Application
    Filed: March 9, 2009
    Publication date: September 17, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Henning STEINHAGEN, Markus FOLLMANN, Jochen GOERLITZER, Herman SCHREUDER
  • Aryl- and Heteroaryl-Ethyl-Acylguanidine Derivatives, Their Preparation and Their Application in Therapeutics
    Publication number: 20090203696
    Abstract: Disclosed are compounds according to formula (I): wherein A, Q, X, Y, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein. The disclosure also relates to pharmaceutical compositions containing a compound of formula (I), to processes for preparing the compounds of formula (I), and to methods of using the compounds of formula (I).
    Type: Application
    Filed: December 15, 2008
    Publication date: August 13, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Jozsef Zsolt BOCSKEI, Gary MCCORT, Hans MATTER, Henning STEINHAGEN, Berangere THIERS
  • Pyrazolopyridine derivatives as inhibitors of beta-Adrenergic Receptor Kinase 1
    Publication number: 20080227777
    Abstract: The invention relates to 6-amido substituted pyrazolopyridine derivatives of the formula (I) useful as inhibitors of beta-adrenergic receptor kinase 1 (?ARK-1), compositions containing such compounds and their use for the treatment and prevention of chronic heart failure, hypertension, myocardial ischemia and hepatitis C virus (HCV) infections, and for the prevention of opiate addiction.
    Type: Application
    Filed: December 20, 2007
    Publication date: September 18, 2008
    Applicant: SANOFI-AVENTIS
    Inventors: Henning STEINHAGEN, Jochen HUBER, Kurt RITTER, Bernard PIRARD, Kirsten BJERGARDE, Marcel PATEK, Martin SMRCINA, Linli WEI